BioNTech to Raise USD 250 Million in Private Placement
The private placement includes an investment in ordinary shares and a investment in 4-year mandatory convertible notes
BioNTech SE announced a private investment of USD 250 million (EUR 223 million) by Temasek and other accredited investors. The private placement includes an investment of approximately USD 139 million in ordinary shares and a USD 112 million investment in 4-year mandatory convertible notes.

Symbolic image
geralt, pixabay.com, CC0
“We are pleased to welcome Temasek onboard as a new shareholder. We believe their long-term investment approach, global presence, and deep experience in the biotechnology field are a good fit with our vision to build a leading global biopharmaceutical company,” said Ugur Sahin, CEO and Co-founder of BioNTech.
Upon closing, private placement investors will receive 2,595,996 ordinary shares in BioNTech, which will be subject to a 180-day lock-up agreement. The 4-year mandatory convertible notes will come with a coupon of 4.5% per annum and a conversion premium of 20% above the reference price. The investment is expected to close in early- to mid-August, subject to customary closing conditions.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security. The securities referenced herein have not been and will not be registered under the Securities Act of 1933, as amended (Securities Act), or applicable state securities laws and may not be offered or sold in the United States or any state thereof absent registration under the Securities Act and applicable state securities laws or an applicable exemption from registration requirements.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Eurofins opens new faciltiy in Livingston
Improving therapies for GI tumors
Actelion submits the registration dossier for macitentan to EMA
ProtAffin AG strengthens Scientific Advisory Board

Study of skin biopsies offers potential as new diagnostic marker for Amyotrophic Lateral Sclerosis - The discovery of this biomarker detectable in small skin samples can be very useful for cases in which diagnosis is difficult
Memory in neural circuits

Fatal overproduction of antibodies - Mutations in plasma cells play a key role in light chain amyloidosis

Click... Resistant bacteria caught in the act! - Scientists have succeeded in capturing unique images of protein soldiers that help bacteria resist drugs
Hesperion announces the opening of its Russian Moscow Office

Takara Bio and Eppendorf cooperate - Automation of Takara Bio’s Chemistries on Eppendorf’s Automated Pipetting Systems for Significantly Higher Efficiency
New genetic links to MS also play roles in other autoimmune diseases
